European Physicians Show Strong Interest in MitraClip System
MENLO PARK, Calif., Sept. 23 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first two patients have been treated with its MitraClip(R) system in Hamburg, Germany. The MitraClip system is the first commercially available device which enables a non-surgical option for patients suffering from the effects of mitral regurgitation (MR).
MR is the second most common type of heart valve insufficiency in Europe, and the most common in the United States, affecting millions of people worldwide. Both in Europe and the United States, the vast majority of patients are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.
The first European patients were treated by the team led by Olaf Franzen, M.D., Dietmar Koschyk, M.D., Hendrik Treede, M.D., and Professor Joachim Schofer, M.D. at the University Heart Center in Hamburg, Germany.
"The immediate results after implanting the MitraClip device have surpassed our initial expectations," said Dr. Franzen, interventionalist for adult structural and congenital heart disease at the University Heart Center.
"The patients we treated last week have heart failure and were considered to be high risk surgical patients," said Professor and Chairman Thomas Meinertz M.D., Ph.D. at the University Heart Center. "Now with the availability of the MitraClip system, we are able to treat these patients with a much less invasive percutaneous alternative for mitral repair."
"This new therapy may be an excellent alternative for this group of
patients with heart failure," said Professor Herrmann Reichenspurner, M.D.,
Ph.D, Head of Cardiac Surgery and Medical Director at the University Heart
Center. "As a cardiac surgeon, there are times when
|SOURCE Evalve, Inc.|
Copyright©2008 PR Newswire.
All rights reserved